Early intraocular pressure after phacoemulsification combined with trabeculectomy.
OBJECTIVE
To determine the efficacy of combined phacoemulsification--trabeculectomy in preventing early postoperative increases in intraocular pressure (IOP).


METHODS
Eighty patients were enrolled in a prospective cohort study. Thirty-six patients with cataracts and uncontrolled glaucoma underwent combined phacoemulsification--trabeculectomy, and 44 patients with cataracts underwent phacoemulsification alone. The operations were performed in a standardized manner by one surgeon. IOP was measured at 4 hours, 1 day, and 7 days after surgery. The need for intervention (digital massage, medications) and the presence of complications were documented.


RESULTS
Four hours after surgery, 5.5% of patients undergoing the combined procedure had IOPs greater than 30 mm Hg, compared with 22.7% of phacoemulsification patients (P < .05). No significant difference in IOP was found between the groups at postoperative day 1 or day 7.


CONCLUSIONS
These results suggest that combined phacoemulsification-trabeculectomy protects against early postoperative elevations in IOP. This finding may influence the surgical management of cataracts in patients with poorly controlled glaucoma and significant compromise of visual field or optic nerve.
Hopkins
J J
JJ
Department of Ophthalmology, University of Toronto, Ontario, Canada.
Apel
A
A
Trope
G E
GE
Rootman
D S
DS
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D002386:Cataract / Q000150:complications; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008916:Miotics / Q000627:therapeutic use; D018918:Phacoemulsification; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D014130:Trabeculectomy; D014792:Visual Acuity
D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D008916:Miotics